Bezielle Selectively Targets Mitochondria of Cancer Cells to Inhibit Glycolysis and OXPHOS

Abstract

Bezielle (BZL101) is a candidate oral drug that has shown promising efficacy and excellent safety in the early phase clinical trials for advanced breast cancer. Bezielle is an aqueous extract from the herb Scutellaria barbata. We have reported previously that Bezielle was selectively cytotoxic to cancer cells while sparing non-transformed cells. In tumor, but not in non-transformed cells, Bezielle induced generation of ROS and severe DNA damage followed by hyperactivation of PARP, depletion of the cellular ATP and NAD, and inhibition of glycolysis. We show here that tumor cells' mitochondria are the primary source of reactive oxygen species induced by Bezielle. Treatment with Bezielle induces progressively higher levels of mitochondrial superoxide as well as peroxide-type ROS. Inhibition of mitochondrial respiration prevents generation of both types of ROS and protects cells from Bezielle-induced death. In addition to glycolysis, Bezielle inhibits oxidative phosphorylation in tumor cells and depletes mitochondrial reserve capacity depriving cells of the ability to produce ATP. Tumor cells lacking functional mitochondria maintain glycolytic activity in presence of Bezielle thus supporting the hypothesis that mitochondria are the primary target of Bezielle. The metabolic effects of Bezielle towards normal cells are not significant, in agreement with the low levels of oxidative damage that Bezielle inflicts on them. Bezielle is therefore a drug that selectively targets cancer cell mitochondria, and is distinguished from other such drugs by its ability to induce not only inhibition of OXPHOS but also of glycolysis. This study provides a better understanding of the mechanism of Bezielle's cytotoxicity, and the basis of its selectivity towards cancer cells.

Association of cancer metabolism-related proteins with oral carcinogenesis – indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?

“…The TUNEL assay demonstrated that tumor cells do not undergo apoptosis and therefore, increased ROS generation by OXPHOS does not reach toxic levels. Based on our results and as currently stated by Whitaker-Menezes et al [57] in the context of breast cancer we assume that mitochondria are the ‘Achilles heel’ and ‘powerhouse’ in the carcinogenesis of OSCC [23,56-59]. Increased levels of ROS in tumor cells are generated by altered metabolic activity, oncogene activation, and deregulated proliferation [60].…”

Metabolic changes during ovarian cancer progression as targets for sphingosine treatment

“…So treatment completely inhibited the modest upregulation of glycolysis to meet ATP needs after FCCP treatment of MOSE-L cells. This has also been observed by other anti-cancer treatments and is thought to be associated with a toxic effect on cancer but not non-transformed cells [42]. This may be tissue specific since the suppression of respiration protects against apoptosis in muscle [43].…”

Mitochondria-targeted antioxidant and glycolysis inhibition

“…This understanding of the molecular mechanisms and implications of both mitochondrial pathways and glycolytic metabolism in cancer has fuelled an increase in research focusing on drugs that target both pathways [13]. Mito-carboxy proxyl (Mito-CP) – a five membered nitroxide (Figure 1) that is covalently linked to a lipophilic triphenylphosphonium cation is a mitochondria-targeted antioxidant.…”